pBud-EGFP/PrP V180I (Met 129)
(Plasmid
#23190)
-
Depositing Lab
-
Depositing OrganizationLady Davis Institute for Medical Research
Located in Canada -
Publication
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 23190 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
Backbone
-
Vector backbonepBudCE4.1-EGFP
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5303
-
Vector typeMammalian Expression, Bacterial Expression
-
Selectable markersZeocin
Growth in Bacteria
-
Bacterial Resistance(s)Bleocin (Zeocin), 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Growth instructionsDH5α in Low-Salt LB
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameHuman Prion Protein
-
Alt namehPrP
-
Alt namePRNP
-
SpeciesH. sapiens (human)
-
Insert Size (bp)762
-
MutationhPrP Mutations: V180I, Met 129 polymorphism.
-
Entrez GenePRNP (a.k.a. ASCR, AltPrP, CD230, CJD, GSS, KURU, PRIP, PrP, PrP27-30, PrP33-35C, PrPc, p27-30)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site ScaI (destroyed during cloning)
- 3′ cloning site XbaI (not destroyed)
- 5′ sequencing primer unknown
- (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Bigenic vector: EGFP under EF-1α promoter, Human Prion Protein under CMV promoter. Ref Plasmid 23027.
Reference:
Jodoin J, Laroche-Pierre S, Goodyer CG, LeBlanc AC.(2007) J Neurosci.27:5081-91.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pBud-EGFP/PrP V180I (Met 129) was a gift from Andrea LeBlanc (Addgene plasmid # 23190) -
For your References section:
Defective retrotranslocation causes loss of anti-Bax function in human familial prion protein mutants. Jodoin J, Laroche-Pierre S, Goodyer CG, LeBlanc AC. J Neurosci. 2007 May 9. 27(19):5081-91. 10.1523/JNEUROSCI.0957-07.2007 PubMed 17494694